Research on Porphyrin Compounds Used in Photodynamic Anticancer and Antimicrobial Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 117
Special Issue Editors
Interests: organic chemistry; porphyrin synthesis; photosensitizers; photodynamic therapy
Special Issue Information
Dear Colleagues,
The unique potential of a photodynamic effect in applications for the treatment of tumor cells and pathogens stems from its multitarget mechanism of action based on oxidative stress. Porphyrins are used as photosensitizers in both types of photodynamic therapies thanks to their good absorption of visible light as well as the ability to produce singlet oxygen and other reactive oxygen species. Furthermore, they can be prepared through a large number of developed synthetic pathways as well as modifications of natural compounds, and can be stable molecules that are non-toxic in the dark. Their structure can be functionalized and modified in many different ways, which allows for the fine tuning of the desired properties.
This Special Issue aims to highlight recent advances in the design, synthesis, and characterization of porphyrin-based compounds, including porphyrin conjugates, toward new photosensitizers with improved properties for anticancer and antimicrobial photodynamic therapy. Improved characteristic(s) in this area can be one or more of the following: higher production of singlet oxygen/ROS, improved drug delivery and increased bioavailability, selectivity for target cells, increased cellular binding/uptake, specific organelle targeting, overpowering hypoxia, and multifunctional activity (including imaging). In achieving these goals, porphyrins can be used in new formulations, as well as in combination therapies, and it is desirable to show the achieving of a required photodynamic effect with lower drug concentrations and lower light doses. Original research articles are welcome in this Special Issue, which may include in vitro and in vivo studies, as well as reviews.
We look forward to receiving your contributions.
Dr. Nela Malatesti
Dr. Ivana Ratkaj
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- porphyrins
- design, synthesis, and characterization
- amphiphilicity/lipophilicity
- drug dose and light dose
- ROS/singlet oxygen production
- anticancer photodynamic therapy
- antimicrobial photodynamic therapy
- hypoxia
- cellular binding/uptake
- in vitro and in vivo studies
